One mGlu5 NAM, dipraglurant, has shown efficacy in phase II trials in neurodegenerative disease, specifically for levodopa-induce dyskinesia in patients with Parkinson’s disease (clinicaltrials.gov: NCT01336088). Here, GRM5 is linked to Parkinson disease.